Eylea, Avastin, and Lucentis are all widely used to treat DME, a consequence of diabetes that can cause blurring of central vision due to the leakage of fluid from abnormal blood vessels in the ...

Eylea, Avastin, and Lucentis are all widely used to treat DME, a consequence of diabetes that can cause blurring of central vision due to the leakage of fluid from abnormal blood vessels in the ...

BETHESDA, Md., Feb. 29 (UPI) --For diabetic macular edema patients with worse eyesight, the drug Eylea offered greater gains in vision than Avastin during the first year of treatment, researchers ...

Avastin is a less expensive anti-VEGF drug ($60 per dose, versus $1850 per dose for Eylea). Avastin is an FDA approved biologic for treating cancer, but is frequently used off-label to treat ...

Indeed, the authors describe the collective clinical benefits favoring Eylea in the present study as “a previously unappreciated advantage” of Eylea over Avastin, which may come as a surprise ...

Eylea, Avastin, and Lucentis all belong to a group of drugs called vascular endothelial growth factor (VEGF) inhibitors. But they don’t all have the same uses.

Eylea and Avastin are both anti-vascular endothelial growth factor injections. But only Eylea is approved to treat retinal diseases. Avastin is typically used to treat certain kinds of cancer.

Regeneron's (REGN) lead drug Eylea's sales decline in the fourth quarter due to a short-term shift to off-label use of Avastin.

U.S. net sales of EYLEA were $736 million, down 39% year-over-year, impacted by increased use of off-label Avastin and lower wholesaler inventory levels. EYLEA HD sales reached $307 million, a 54% ...

A two-year clinical trial that compared three drugs for diabetic macular edema (DME) found that gains in vision were greater for participants receiving the drug Eylea (aflibercept) than for those ...